ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Eligibility Criteria

• * Age \> 18 years old AND
• * Were treated with curative intent AND
• * Are planning to undergo regular follow-up and monitoring for cancer recurrence per standard of care at the enrolling site AND
• * Provided written informed consent to participate in the study AND
• * Are willing to have de-identified clinical data shared with investigators at regular intervals as outlined in the study protocol and informed consent AND
• * Are willing to provide blood samples at enrollment and at subsequent clinical visits coinciding with standard of care follow-up, for up to 5 years as outlined in the study protocol and informed consent AND
• * Have at least one blood sample collected 4-12 weeks after completion of primary treatment of the Index Cancer
• * Have a histologically confirmed Index Cancer that qualifies for inclusion, defined as:
• * Cohort 1: Muscle invasive carcinoma of the bladder, ureter, or renal pelvis (stage II-III),
• * Cohort 2: Non-small cell lung cancer (stage II-III),
• * Cohort 3: Invasive breast carcinoma with all of the following:
• * Cohort 4: Stage IIb-III cutaneous melanoma or limited (resectable) stage IV melanoma treated with curative intent,
• * Cohort 5: Esophageal or gastroesophageal junction carcinoma (stage II-III),
• * Cohort 6: Gastric adenocarcinoma (stage II-III),
• * Cohort 7: Surgically resected pancreatic adenocarcinoma,
• * Cohort 8: Invasive squamous cell carcinoma of the head and neck (includes stage I-III oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, nasal cavity, paranasal sinus, and salivary gland cancers),
• * Cohort 9: High-risk epithelial ovarian or Fallopian tube carcinoma (defined as stage IC-III or stage I that has high grade (grade 3-4) or clear cell histology),
• * Cohort 10: High-risk endometrial carcinoma (defined as having any of the following: serous or clear cell adenocarcinoma histology (any stage), grade 3 or 4 deeply invasive (T1b or greater) endometrioid carcinoma, stage III disease (any histology)),
• * Cohort 11: High-risk renal cell carcinoma (defined as high grade (grade 3-4) stage II, stage III or limited (resectable) stage IV treated with curative intent)
• * History of allogeneic organ or tissue transplant
• * Index cancer has neuroendocrine histology
• * History of another primary cancer, with the exception of the following (if adequately treated and the patient is without evidence of disease at the time of enrollment): in situ cancers, non-melanoma skin carcinoma, localized low-risk prostate cancer (Gleason score \< 6) with PSA in the normal range, and stage I papillary thyroid carcinoma.
• * Known distant metastasis at time of enrollment (with the exception of participants with limited/resectable stage IV cutaneous melanoma or RCC)
• * Is participating in a clinical trial or another observational study that is evaluating the performance of another genomic test in the post-treatment surveillance setting at predicting/detecting recurrence